H.C. Wainwright assumed coverage of Verrica Pharmaceuticals with a Buy rating and $12 price target. The company reported \"encouraging\" Ycanth volume in Q1, the analyst tells investors in a research note. The firm says the common warts indication \"appears positioned to drive rapid long-term sales expansion\" for Verrica.
